Pfizer ends study on potential lung cancer drug San Francisco Chronicle It concluded that figitumumab in conjunction with Tarceva will likely not significantly improve the overall survival rate of patients. ...
Pfizer ends study on potential lung cancer drug Marin Independent-Journal It concluded that figitumumab in conjunction with Tarceva will likely not significantly improve the overall survival rate of patients. ...
BC cancer researchers make lymphoma 'breakthrough' Calgary Herald In the study, which investigated patient records, the 10-year survival rate in patients with the highest number of the macrophages was 59.6 per cent ...
Pfizer ends study on potential lung cancer drug Houston Chronicle It concluded that figitumumab in conjunction with Tarceva will likely not significantly improve the overall survival rate of patients. ...
Pfizer ends study on potential lung cancer drug Fort Worth Star Telegram It concluded that figitumumab in conjunction with Tarceva will likely not significantly improve the overall survival rate of patients. ...
Pfizer ends study on potential lung cancer drug News 10NBC It concluded that figitumumab in conjunction with Tarceva will likely not significantly improve the overall survival rate of patients. ...
Pfizer ends study on potential lung cancer drug Tuscaloosa News (subscription) It concluded that figitumumab in conjunction with Tarceva will likely not significantly improve the overall survival rate of patients. ...
Pfizer ends study on potential lung cancer drug York Daily Record It concluded that figitumumab in conjunction with Tarceva will likely not significantly improve the overall survival rate of patients. ...
Pfizer ends study on potential lung cancer drug San Jose Mercury News It concluded that figitumumab in conjunction with Tarceva will likely not significantly improve the overall survival rate of patients. ...
